AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35532871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 102
Study 35532871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 35532871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 102
Study 36419388 — intervention group
Group type: EXPERIMENTAL
Intervention: BV-4051
Number of subjects: 208
Study 36419388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 33508779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration trial (humid heat at 40 °C, 60% relative humidity with exercise)
Number of subjects: 11
Study 33508779 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydration trial (ingestion of lightly salted water)
Number of subjects: 11
Study 33508779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements
Number of subjects: 11
Study 33508779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound estimates of body fat percentage
Number of subjects: 11
Study 32197627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioural therapy
Number of subjects: 0
Study 32197627 — intervention group
Group type: COMPARATOR
Intervention: Supportive listening intervention
Number of subjects: 0
Study 34591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DCb) for six cycles
Number of subjects: 93
Study 34591977 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles (EC-D)
Number of subjects: 93
Study 34591977 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and event-free survival (EFS) rates
Number of subjects: 93
Study 33705165 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK intervention (behavioral exercises within three individual sessions)
Number of subjects: 176
Study 33705165 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK intervention
Number of subjects: 176
Study 33705165 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 176
Study 33264516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 3 mg/kg
Number of subjects: 24
Study 33264516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 30 mg/kg
Number of subjects: 24
Study 33264516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33264516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab (both doses)
Number of subjects: 24
Study 33427489 — intervention group
Group type: EXPERIMENTAL
Intervention: MACI with ABG
Number of subjects: 21
Study 35843845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric and supportive care assessments from a multidisciplinary team targeting unmet needs.
Number of subjects: 200
Study 35843845 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine oncological management with referral to geriatrics based on discretion of the primary oncologist).
Number of subjects: 200
Study 32901293 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin T (HS‐cTnT) levels measured with a highly sensitive assay
Number of subjects: 442
Study 35570159 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 727
Study 35570159 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 727
Study 32800842 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP treatment
Number of subjects: 50
Study 32800842 — intervention group
Group type: COMPARATOR
Intervention: Predialysis BP treatment
Number of subjects: 50
Study 32544142 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-only method
Number of subjects: 25
Study 32544142 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved validation method
Number of subjects: 25
Study 32397994 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach hospital rehabilitation services in residential aged care
Number of subjects: 13
Study 32397994 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies in addition to investment in rehabilitation services
Number of subjects: 13
Study 32397994 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased focus on rehabilitation in residential care
Number of subjects: 13
Study 35191173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based physical activity (walk-in nature)
Number of subjects: 0
Study 35191173 — intervention group
Group type: COMPARATOR
Intervention: Sit-in nature (control group)
Number of subjects: 0
Study 34076379 — intervention group
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata L
Number of subjects: 20
Study 34076379 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study 35726085 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutics (DTx) + guideline-based lifestyle modification consultation treatment as usual (TAU)
Number of subjects: 0
Study 35726085 — intervention group
Group type: COMPARATOR
Intervention: TAU-only strategy
Number of subjects: 0
Study 35726085 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio (ICER) for DTx + TAU
Number of subjects: 0
Study 35726085 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of DTx being cost-effective
Number of subjects: 0
Study 33231256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia (CBTi)
Number of subjects: 91
Study 33231256 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 91
Study 33105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low artifact removal during controlled breathing
Number of subjects: 41
Study 33105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low artifact removal during spontaneous breathing
Number of subjects: 41
Study 33105371 — intervention group
Group type: COMPARATOR
Intervention: Strong artifact removal
Number of subjects: 41
Study 33105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-domain and nonlinear parameters
Number of subjects: 41
Study 33105371 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV monitoring
Number of subjects: 41
Study 33105371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersession differences in HRV measurements <30%
Number of subjects: 41
Study 35545190 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided sodium hyaluronate injections
Number of subjects: 40
Study 35545190 — intervention group
Group type: COMPARATOR
Intervention: Conventional sodium hyaluronate injections
Number of subjects: 40
Study 33576545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/Acetaminophen 650 mg
Number of subjects: 154
Study 33576545 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 154
Study 33576545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Number of subjects: 154
Study 33576545 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 154
Study 33196737 — intervention group
Group type: EXPERIMENTAL
Intervention: USCCM cream and serum pre‐ and post‐ ablative resurfacing
Number of subjects: 20
Study 33196737 — intervention group
Group type: COMPARATOR
Intervention: Vehicle pre‐procedure cream
Number of subjects: 20
Study 35763871 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 cycles of ifosfamide, vincristine and dactinomycin; some patients also received doxorubicin and/or maintenance if enrolled in the randomised studies.
Number of subjects: 143
Study 34665204 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch for 12 weeks
Number of subjects: 1251
Study 34665204 — intervention group
Group type: COMPARATOR
Intervention: Varenicline monotherapy for 12 weeks
Number of subjects: 1251
Study 34665204 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch for 24 weeks
Number of subjects: 1251
Study 34665204 — intervention group
Group type: COMPARATOR
Intervention: Varenicline monotherapy for 24 weeks
Number of subjects: 1251
Study 34665204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea occurrence across groups
Number of subjects: 1251
Study 34665204 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia occurrence across groups
Number of subjects: 1251
Study 32304283 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin/sitagliptin dual therapy for 16 weeks
Number of subjects: 972
Study 32304283 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin/sitagliptin triple therapy for 24 weeks
Number of subjects: 972
Study 32304283 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 972
Study 32304283 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 972
Study 36074950 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ lithotripsy
Number of subjects: 68
Study 36074950 — intervention group
Group type: COMPARATOR
Intervention: Relocation lithotripsy
Number of subjects: 68
Study 32720187 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin (TI)
Number of subjects: 5505
Study 32720187 — intervention group
Group type: COMPARATOR
Intervention: Technosphere inhalation powder without insulin (TP; placebo)
Number of subjects: 5505
Study 32720187 — intervention group
Group type: COMPARATOR
Intervention: Active-comparator treatment
Number of subjects: 5505
Study 32720187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TI therapy
Number of subjects: 5505
Study 32720187 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic monitoring
Number of subjects: 5505
Study 33121885 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 557
Study 33121885 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial anesthesia
Number of subjects: 557
Study 34107851 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound programme (MUSP) at baseline
Number of subjects: 126
Study 34107851 — intervention group
Group type: COMPARATOR
Intervention: No MUSP (control group)
Number of subjects: 126
Study 34107851 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasound programme (MUSP)
Number of subjects: 126
Study 32567340 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session disclosure-support intervention
Number of subjects: 80
Study 32567340 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 32394650 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion intervention
Number of subjects: 100
Study 32394650 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 100
Study 35653732 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone algorithm-assisted insulin delivery (DH-AID)
Number of subjects: 58
Study 35653732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone algorithm-assisted insulin delivery (SH-AID)
Number of subjects: 58
Study 35653732 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 34782232 — intervention group
Group type: EXPERIMENTAL
Intervention: PROficiency based StePwise Endovascular Curricular Training (PROSPECT)
Number of subjects: 48
Study 33638931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 227
Study 33638931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 35722816 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 219
Study 35722816 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study 32734751 — intervention group
Group type: COMPARATOR
Intervention: Virtual Training (VT)
Number of subjects: 55
Study 32734751 — intervention group
Group type: COMPARATOR
Intervention: Plyometric Training (PT)
Number of subjects: 55
Study 32734751 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 55
Study 35445362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure in Primary Care (PE-PC)
Number of subjects: 30
Study 36086254 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Biofeedback-based Balance Intervention (CBBI)
Number of subjects: 13
Study 36086254 — intervention group
Group type: COMPARATOR
Intervention: Control group (TBI-CTL)
Number of subjects: 13
Study 33524314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg orally once daily for 3 years)
Number of subjects: 160
Study 33524314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral once daily for 3 years)
Number of subjects: 160
Study 36056410 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient liners (RL)
Number of subjects: 132
Study 36056410 — intervention group
Group type: COMPARATOR
Intervention: Non-resilient liners (NRL)
Number of subjects: 132
Study 33316362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive planning (AP) using a minimization algorithm, 36 Gy in 6 weekly fractions.
Number of subjects: 65
Study 33316362 — intervention group
Group type: COMPARATOR
Intervention: Standard planning (SP), 36 Gy in 6 weekly fractions.
Number of subjects: 65
Study 33316362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 65
Study 616562814 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Life Practice (HLP) education, 10 health education sessions
Number of subjects: 101
Study 616562814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 34031151 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support (additional clinical backfill funding and unit-level QI microcoaching)
Number of subjects: 48
Study 34031151 — intervention group
Group type: COMPARATOR
Intervention: Standard support (QI toolkit and regional-level support for a midwife/obstetric 'champion')
Number of subjects: 48
Study 35578194 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment (20 sessions, add-on to individual therapy)
Number of subjects: 59
Study 35578194 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy alone
Number of subjects: 59
Study 35578194 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment
Number of subjects: 59
Study 34333783 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication via social media before the operation (group 2)
Number of subjects: 143
Study 34333783 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication via social media before and after the operation (group 3)
Number of subjects: 143
Study 34333783 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication via social media only after the operation (group 1)
Number of subjects: 143
Study 34333783 — intervention group
Group type: COMPARATOR
Intervention: No communication on social media (control group 4)
Number of subjects: 143
Study 32448387 — intervention group
Group type: EXPERIMENTAL
Intervention: ePain (6-week online pain management programme)
Number of subjects: 0
Study 32448387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34275193 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing followed by ultrasonic calculus removal (A+US)
Number of subjects: 41
Study 34275193 — intervention group
Group type: COMPARATOR
Intervention: Traditional full-mouth ultrasonic debridement followed by polishing with a rubber cup and prophylactic paste (US+P)
Number of subjects: 41
Study 35758504 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (50 units)
Number of subjects: 102
Study 35758504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese botulinum toxin type A (CBA) (50 units)
Number of subjects: 102
Study 33641535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ankle Exercise with Intermittent Pneumatic Compression (IPC)
Number of subjects: 20
Study 33641535 — intervention group
Group type: COMPARATOR
Intervention: Active Ankle Exercise (AAE) alone
Number of subjects: 20
Study 33641535 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Pneumatic Compression (IPC) alone
Number of subjects: 20
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with oxygen permeability of 65 Dk
Number of subjects: 15
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with oxygen permeability of ≥100 Dk
Number of subjects: 15
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: All oxygen‐permeable lenses
Number of subjects: 15
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤125 Dk lenses
Number of subjects: 15
Study 32932393 — intervention group
Group type: COMPARATOR
Intervention: Soft lenses
Number of subjects: 15
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: 180+ Dk lenses
Number of subjects: 15
Study 32932393 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lens wear
Number of subjects: 15
Study 34860287 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 34860287 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33637544 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Assisted Lifestyle (PAL) intervention
Number of subjects: 461
Study 33637544 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 461
Study 33085967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 7119
Study 35301728 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented training strategy
Number of subjects: 96
Study 35301728 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-oriented training strategy
Number of subjects: 96
Study 33710658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure testing
Number of subjects: 96
Study 33710658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure testing with pedicle fat
Number of subjects: 96
Study 33710658 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvesting the vein with the pedicle fat
Number of subjects: 96
Study 33710658 — intervention group
Group type: COMPARATOR
Intervention: Conventional saphenous vein graft preparation with low-pressure distension
Number of subjects: 96
Study 35666503 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Healthy Living intervention
Number of subjects: 9840
Study 32655132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 30
Study 32655132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high intensity aerobic and strengthening training
Number of subjects: 178
Study 35745256 — intervention group
Group type: COMPARATOR
Intervention: Low‐impact PA
Number of subjects: 178
Study 33910498 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism spectrum disorder
Number of subjects: 14654
Study 33910498 — intervention group
Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 14654
Study 32561500 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 42
Study 33496068 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen (0.1 mL of Candida albicans antigen injected monthly in one patch of alopecia)
Number of subjects: 48
Study 33496068 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroid (0.1 mL of triamcinolone acetonide injected monthly in all alopecia patches)
Number of subjects: 48
Study 33496068 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen
Number of subjects: 48
Study 33496068 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroid
Number of subjects: 48
Study 33023521 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided counseling (monthly for four consecutive months)
Number of subjects: 258
Study 33023521 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided counseling (direct effect)
Number of subjects: 258
Study 33023521 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided counseling (indirect effect)
Number of subjects: 258
Study 33023521 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine nutrition education)
Number of subjects: 258
Study 33400792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Number of subjects: 53
Study 33400792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 34184130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam plus haloperidol
Number of subjects: 58
Study 34184130 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 58
Study 34184130 — intervention group
Group type: EXPERIMENTAL
Intervention: RASS improvement
Number of subjects: 58
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant Treatment Record (ATR) classification level 1
Number of subjects: 97
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant Treatment Record (ATR) classification level 2
Number of subjects: 97
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant Treatment Record (ATR) classification level ≥3
Number of subjects: 97
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with serotonin norepinephrine reuptake inhibitors (SNRIs)
Number of subjects: 97
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with dopamine norepinephrine reuptake inhibitors (DNRIs)
Number of subjects: 97
Study 32315537 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with mixed dopamine serotonin receptor antagonists
Number of subjects: 97
Study 36497905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure injury E‐book app training program
Number of subjects: 164
Study 36497905 — intervention group
Group type: COMPARATOR
Intervention: Conventional education program
Number of subjects: 164
Study 32950546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/betamethasone dipropionate 0.064% foam (Cal/BD)
Number of subjects: 545
Study 32950546 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam (reactive management)
Number of subjects: 545
Study 32677499 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (video simulation of seizure first aid)
Number of subjects: 83